Cancer Lett. 2017 Jan 28;385:1-11.
The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects.
García-Vilas JA, Pino-Ángeles A, Martínez-Poveda B, Quesada AR, Medina MÁ.
In vitro assays were conducted to determine the effects of damnacanthal on steps in the angiogenic process, including inhibition of tubulogenesis, endothelial cell proliferation, survival, migration and production of extracellular matrix remodeling enzyme. The results suggest that damancanthal may be of interest for the treatment of cancer and other angiogenesis-dependent diseases. (original abstract available at https://www.ncbi.nlm.nih.gov/pubmed/27816491).